TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31139138

Group type: EXPERIMENTAL
Intervention: Bruxism Episode Index in patients with significant headache impact (HIT-6 score ≥ 50)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bruxism associated with arousal
Number of subjects: 0
Study: 31139146

Group type: EXPERIMENTAL
Intervention: IVF treatment following POSEIDON criteria
Number of subjects: 4828
Study: 31139420

Group type: EXPERIMENTAL
Intervention: Individualized strength training program based on MEP amplitude (low: 35-50% 1RM, moderate: 50-65% 1RM, high: 70-80% 1RM) combined with anodal tDCS.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Individualized strength training program based on MEP amplitude (low, moderate, high) combined with sham tDCS.
Number of subjects: 84
Study: 31139423

Group type: EXPERIMENTAL
Intervention: Transnasal gastroscopy (nEGD)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Peroral gastroscopy (oEGD)
Number of subjects: 196
Study: 31139431

Group type: EXPERIMENTAL
Intervention: VR-CBT intervention (8 weekly group sessions)
Number of subjects: 7
Study: 31139441

Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary foods (RUSF; PlumpySup)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specially formulated corn-soy blend (CSB++; Super Cereal Plus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misola (micronutrient-fortified cereal-legume blend)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Locally milled flour (LMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No MAM treatment
Number of subjects: 0
Study: 31139442

Group type: EXPERIMENTAL
Intervention: Automated call and text immunisation reminders
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study: 31139640

Group type: EXPERIMENTAL
Intervention: Fresh pomegranate juice (PJ) at 1.5 mL per kg body weight
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 59
Study: 31139766

Group type: EXPERIMENTAL
Intervention: 4 mg folic acid/d (higher strength)
Number of subjects: 345

Group type: COMPARATOR
Intervention: 0.8 mg folic acid/d (standard of care)
Number of subjects: 345
Study: 31139996

Group type: EXPERIMENTAL
Intervention: Laparoscopic bilateral groin hernia repair with one large self-fixating mesh
Number of subjects: 100
Study: 31140003

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 601

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (younger than 70)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (older subgroup)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (advanced stages)
Number of subjects: 601
Study: 31140199

Group type: EXPERIMENTAL
Intervention: School staff measurements of height and weight
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Researcher measurements of height and weight
Number of subjects: 1008
Study: 31140667

Group type: EXPERIMENTAL
Intervention: Labels used to describe themselves and when speaking with others who use drugs, with family and with treatment providers
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Preferred labels for others to call them
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Labels participants never wanted to be called
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Use of slang terms
Number of subjects: 263
Study: 31141105

Group type: EXPERIMENTAL
Intervention: Genetic risk score based on 3 common Lp(a)-raising variants
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: High Lp(a) levels (≥60 mg/dL) in first-degree relatives of patients with CAVS
Number of subjects: 1009
Study: 31141592

Group type: EXPERIMENTAL
Intervention: Prolate spheroidal coordinate system for mapping cardiac imaging data
Number of subjects: 0
Study: 31141631

Group type: EXPERIMENTAL
Intervention: Ibrutinib and Venetoclax
Number of subjects: 80
Study: 31141830

Group type: EXPERIMENTAL
Intervention: EHR-integrated patient portal
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (pre-intervention)
Number of subjects: 55
Study: 31142037

Group type: EXPERIMENTAL
Intervention: First-line triplet or doublet chemotherapy combined with targeted therapy
Number of subjects: 0
Study: 31142305

Group type: EXPERIMENTAL
Intervention: Food-insecure students
Number of subjects: 855

Group type: COMPARATOR
Intervention: Students with on-campus pantry awareness
Number of subjects: 855

Group type: COMPARATOR
Intervention: Food-insecure students utilizing the pantry
Number of subjects: 855
Study: 31142314

Group type: EXPERIMENTAL
Intervention: Oxygen use at rest
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Lower forced vital capacity (FVC) % predicted
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Lower diffusion capacity for carbon monoxide (DLco) % predicted
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Age ≥62 years
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Age <62 years
Number of subjects: 662
Study: 31142357

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 41
Study: 31142450

Group type: EXPERIMENTAL
Intervention: High consumption of ultra-processed foods (highest quarter)
Number of subjects: 19899

Group type: EXPERIMENTAL
Intervention: Each additional serving of ultra-processed foods
Number of subjects: 19899

Group type: EXPERIMENTAL
Intervention: Higher consumption of ultra-processed foods (>4 servings daily)
Number of subjects: 19899
Study: 31142457

Group type: EXPERIMENTAL
Intervention: High consumption of ultra-processed foods (fourth quarter)
Number of subjects: 105159

Group type: COMPARATOR
Intervention: Low consumption of ultra-processed foods (first quarter)
Number of subjects: 105159
Study: 31142503

Group type: EXPERIMENTAL
Intervention: CIV rhIL15 at 2 μg/kg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CIV rhIL15 at various doses (0.125, 0.25, 0.5, 1, 2, or 4 μg/kg/day)
Number of subjects: 27
Study: 31142507

Group type: EXPERIMENTAL
Intervention: Voxel Forecast multiscale regression framework for predicting tumor voxel standardized uptake value (SUV) on PETmid from baseline patient-level and voxel-level covariates.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined patient- and voxel-level forecasts using Voxel Forecast.
Number of subjects: 25
Study: 31142518

Group type: EXPERIMENTAL
Intervention: Knee pain group
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 504
Study: 31142594

Group type: EXPERIMENTAL
Intervention: ECG criteria for AMI diagnosis
Number of subjects: 8830

Group type: EXPERIMENTAL
Intervention: hs-cTnT and hs-cTnI concentrations at presentation
Number of subjects: 8830

Group type: EXPERIMENTAL
Intervention: Diagnostic algorithm combining ECG criteria with hs-cTnT/I concentrations
Number of subjects: 8830
Study: 31143111

Group type: EXPERIMENTAL
Intervention: Multi-ingredient nutritional supplementation with exercise training
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Multi-ingredient nutritional supplementation without exercise training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 49
Study: 31143160

Group type: EXPERIMENTAL
Intervention: Soy Protein with Isoflavones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soy Protein without Isoflavones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocoa with Isoflavones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocoa without Isoflavones
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31143849

Group type: EXPERIMENTAL
Intervention: Sorghum-based fortified blended foods (FBFs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cowpea-based fortified blended foods (FBFs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extruded corn-soy blend 14
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corn-soy blend plus (CSB+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 31143877

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 921

Group type: COMPARATOR
Intervention: Inflammation-exposed anhaptoglobinemic or hypohaptoglobinemic (Category 3)
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Hp1-2 or Hp2-2 phenotypes
Number of subjects: 921
Study: 31143880

Group type: EXPERIMENTAL
Intervention: Trabectedin (T) at dose level 1 (1.5 mg/m2) in combination with radiation therapy (RT) (45 Gy in 25 fractions of 1.8 Gy each)
Number of subjects: 14
Study: 31144666

Group type: EXPERIMENTAL
Intervention: AA plus smartphone app (n=19)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: AA alone (n=19)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Waitlist control (n=21)
Number of subjects: 59
Study: 31144670

Group type: EXPERIMENTAL
Intervention: Sleep education plus PHM device (Shine 2, Misfit)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sleep education alone
Number of subjects: 100
Study: 31145415

Group type: EXPERIMENTAL
Intervention: Intravenous administration of PF-06801591 at escalating doses (0.5, 1, 3, or 10 mg/kg) every 3 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of PF-06801591 at a single dose level of 300 mg every 4 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall response rate for both intravenous and subcutaneous administration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of PF-06801591
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PD-1 receptor occupancy
Number of subjects: 40
Study: 31145418

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX and losartan for 8 cycles followed by chemoradiotherapy (short-course or long-course depending on resectability)
Number of subjects: 49
Study: 31145440

Group type: EXPERIMENTAL
Intervention: Argus II Retinal Prosthesis
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Argus II Retinal Prosthesis On
Number of subjects: 47

Group type: COMPARATOR
Intervention: Argus II Retinal Prosthesis Off
Number of subjects: 47
Study: 31146167

Group type: EXPERIMENTAL
Intervention: Exosomal miR-141-3p
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Exosomal miR-375
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: High exosomal miR-141-3p
Number of subjects: 93
Study: 31146700

Group type: EXPERIMENTAL
Intervention: CHD7 gene variants
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cranial MRI analysis
Number of subjects: 12
Study: 31146712

Group type: EXPERIMENTAL
Intervention: Impact of Event Scale Revised (IES-R) for assessing risk of PTSD
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: PTSD Check List for DSM-5 (PCL-5) at 3 months
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression model
Number of subjects: 1500
Study: 31146732

Group type: EXPERIMENTAL
Intervention: XN-30
Number of subjects: 16

Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Malaria rapid diagnostic tests (HRP-2/pLDH)
Number of subjects: 16
Study: 31146808

Group type: EXPERIMENTAL
Intervention: Valve-in-valve TAVR
Number of subjects: 365
Study: 31147129

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 102
Study: 31147139

Group type: EXPERIMENTAL
Intervention: Zenith Dissection Endovascular System (William Cook Europe)
Number of subjects: 86
Study: 31147146

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent cisplatin and radiation therapy (CRT)
Number of subjects: 30
Study: 31147302

Group type: EXPERIMENTAL
Intervention: GLPG1837 (three increasing dosages twice-daily for two 7-day and one 14-day period)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: GLPG1837 (after one-week ivacaftor washout)
Number of subjects: 32

Group type: COMPARATOR
Intervention: ivacaftor (one-week washout)
Number of subjects: 32
Study: 31147307

Group type: EXPERIMENTAL
Intervention: Quantitative aortography using videodensitometry
Number of subjects: 354

Group type: COMPARATOR
Intervention: Previous validation studies (RESPOND population)
Number of subjects: 354

Group type: COMPARATOR
Intervention: CT planning strategy
Number of subjects: 354

Group type: COMPARATOR
Intervention: Teng's rule planning strategy
Number of subjects: 354

Group type: COMPARATOR
Intervention: Circle planning strategy
Number of subjects: 354

Group type: COMPARATOR
Intervention: 3mensio planning strategy
Number of subjects: 354
Study: 31147686

Group type: EXPERIMENTAL
Intervention: Oropharyngeal colostrum (OPC)
Number of subjects: 1006
Study: 31147927

Group type: EXPERIMENTAL
Intervention: PSMA-targeted PET/CT
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 14
Study: 31148056

Group type: EXPERIMENTAL
Intervention: Conservative or surgical treatment for LUTS/BPH
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Holter monitoring
Number of subjects: 83
Study: 31148336

Group type: EXPERIMENTAL
Intervention: RIP3 promoter variant rs3212247
Number of subjects: 3194

Group type: EXPERIMENTAL
Intervention: RIP3 promoter variant rs3212247 CC genotype
Number of subjects: 3194

Group type: COMPARATOR
Intervention: RIP3 missense variant rs3212254
Number of subjects: 3194
Study: 31148501

Group type: EXPERIMENTAL
Intervention: Exercise motivation
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Exercise attitudes
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Exercise self-concept
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Exercise support from friends
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Places for walking and cycling
Number of subjects: 166
Study: 31148544

Group type: EXPERIMENTAL
Intervention: Automated mobile phone-based personalized messages (SMS or automated call)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Different types of automated SMS text or calls
Number of subjects: 250
Study: 31150484

Group type: EXPERIMENTAL
Intervention: Comprehensive primary school-based health intervention program
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control group (matched schools)
Number of subjects: 380
Study: 31150817

Group type: EXPERIMENTAL
Intervention: S-ICD with shock energy of 65 J
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: S-ICD with a vector programmed with a 2× gain
Number of subjects: 570
Study: 31151383

Group type: EXPERIMENTAL
Intervention: Reveal LINQ ICM insertion
Number of subjects: 191
Study: 31151405

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 25M pCPC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 50M pCPC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracoronary infusion of vehicle (Control)
Number of subjects: 0
Study: 31151409

Group type: EXPERIMENTAL
Intervention: 12-week community-based pulmonary rehabilitation (PR)
Number of subjects: 73
Study: 31151438

Group type: EXPERIMENTAL
Intervention: Knowledge-based palliative care intervention consisting of five 2-h seminars during a 6-month period.
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 365
Study: 31151483

Group type: EXPERIMENTAL
Intervention: Surgical trial (CREST-2)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Antithrombotic trials (NAVIGATE-ESUS, DATAS-II)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Non-randomized external monitoring device study (PROPHECY)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Gender comparison
Number of subjects: 235
Study: 31151904

Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 50
Study: 31151984

Group type: EXPERIMENTAL
Intervention: Haploidentical HCT/kidney transplantation with fludarabine, cyclophosphamide, total-body irradiation, and GVHD prophylaxis (post-HCT cyclophosphamide, tacrolimus, mycophenolate mofetil)
Number of subjects: 6
Study: 31152037

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIII Fc (rFVIIIFc)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Conventional factor products
Number of subjects: 350
Study: 31152361

Group type: EXPERIMENTAL
Intervention: Online weight management program plus population health management (PHM) support from primary care practices
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Proposed online program
Number of subjects: 13
Study: 31152555

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine administered twice daily for 3 days
Number of subjects: 397
Study: 31152670

Group type: EXPERIMENTAL
Intervention: Highest quartile of the Alternate Dietary Inflammatory Index (ADII)
Number of subjects: 26730

Group type: EXPERIMENTAL
Intervention: Highest quartile of the ADII among women
Number of subjects: 26730

Group type: EXPERIMENTAL
Intervention: Highest quartile of the ADII among middle-age adults
Number of subjects: 26730

Group type: EXPERIMENTAL
Intervention: Highest quartile of the ADII among participants with BMI ≥25
Number of subjects: 26730
Study: 31152705

Group type: EXPERIMENTAL
Intervention: REACH intervention (combined outpatient and home PT with app and tablet)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (propensity matched controls, n=100)
Number of subjects: 75
Study: 31152738

Group type: EXPERIMENTAL
Intervention: EUS-guided drainage with the newly designed LAMS (Niti-S SPAXUS)
Number of subjects: 34
Study: 31153765

Group type: EXPERIMENTAL
Intervention: Recurrent upper respiratory infections, gastroesophageal reflux, and neck trauma as extrinsic risk factors for SD.
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Functional MRI analysis of a subset of SD patients.
Number of subjects: 186
Study: 31153920

Group type: EXPERIMENTAL
Intervention: Direct and indirect costs incurred by caregivers in El Salvador
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Government-paid hospitalization costs in El Salvador
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Overall societal cost of severe ARI in El Salvador
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Direct and indirect costs incurred by caregivers in Panama
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Health-care system costs in Panama
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Overall societal cost of severe ARI in Panama
Number of subjects: 638
Study: 31154041

Group type: EXPERIMENTAL
Intervention: Comprehensive symptom and comorbidity questionnaires, spirometry, CT scans of the chest, and genetic and biomarker profiling
Number of subjects: 10000
Study: 31154312

Group type: EXPERIMENTAL
Intervention: Cancer Clinical Trials (CCT)
Number of subjects: 199
Study: 31154457

Group type: EXPERIMENTAL
Intervention: Pembrolizumab, 200 mg, administered intravenously every 3 weeks for up to 35 doses.
Number of subjects: 30
Study: 31154522

Group type: EXPERIMENTAL
Intervention: Exercise in hypoxia
Number of subjects: 37
Study: 31154634

Group type: EXPERIMENTAL
Intervention: ACR20 achievement
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: MDA achievement
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: HAQ-DI MCID achievement (improvement ≥ 0.35)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Presenteeism improvement
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Work productivity loss improvement
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Activity impairment improvement
Number of subjects: 780
Study: 31154919

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 550
Study: 31154995

Group type: EXPERIMENTAL
Intervention: Counseling on appropriate infant feeding and WASH practices for six months (monthly visits)
Number of subjects: 20
Study: 31155412

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31155600

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV), administered in a three-vaccination regimen (Day 1, Months 2 and 6)
Number of subjects: 100
Study: 31155658

Group type: EXPERIMENTAL
Intervention: Metabolomics data from Metabolon, Inc. (14 cohorts)
Number of subjects: 136000

Group type: EXPERIMENTAL
Intervention: Metabolomics data from the Broad Institute (15 cohorts)
Number of subjects: 136000
Study: 31155932

Group type: EXPERIMENTAL
Intervention: Risk prediction model for life-threatening ventricular tachyarrhythmia (LTVTA)
Number of subjects: 839

Group type: COMPARATOR
Intervention: Risk prediction model for LTVTA
Number of subjects: 839
Study: 31156069

Group type: EXPERIMENTAL
Intervention: Self-reported cigarette smoking in adults with ADHD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-reported cigarette smoking in adults without ADHD
Number of subjects: 0
Study: 31156406

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31156538

Group type: EXPERIMENTAL
Intervention: Parenteral Phenobarbital
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral Phenytoin
Number of subjects: 0
Study: 31156861

Group type: EXPERIMENTAL
Intervention: Pharmacy care intervention involving motivational interviews, delivered by community pharmacists face-to-face or by telephone, as part of the New Medicine Service or a Medication Usage Review, lasting 15-20 minutes.
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 71
Study: 31157039

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 118
Study: 31157074

Group type: EXPERIMENTAL
Intervention: 90 mM trisodium citrate solution
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 35 mM trisodium citrate solution
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both 35 mM and 90 mM trisodium citrate solutions
Number of subjects: 2
Study: 31157595

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Prospective frailty index (FI)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Retrospective frailty index (FI)
Number of subjects: 401
Study: 31157653

Group type: EXPERIMENTAL
Intervention: Red cell transfusion (intra-operative)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Red cell transfusion (day 1 or 2)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Red cell transfusion
Number of subjects: 61
Study: 31157681

Group type: EXPERIMENTAL
Intervention: Infants (younger children)
Number of subjects: 204
Study: 31157746

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg b.i.d. for 5 days
Number of subjects: 60